David Gurwitz

9.8k total citations · 1 hit paper
193 papers, 5.8k citations indexed

About

David Gurwitz is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Genetics. According to data from OpenAlex, David Gurwitz has authored 193 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Molecular Biology, 43 papers in Cellular and Molecular Neuroscience and 33 papers in Genetics. Recurrent topics in David Gurwitz's work include Receptor Mechanisms and Signaling (31 papers), Pharmacogenetics and Drug Metabolism (25 papers) and Neuroscience and Neuropharmacology Research (23 papers). David Gurwitz is often cited by papers focused on Receptor Mechanisms and Signaling (31 papers), Pharmacogenetics and Drug Metabolism (25 papers) and Neuroscience and Neuropharmacology Research (23 papers). David Gurwitz collaborates with scholars based in Israel, United States and United Kingdom. David Gurwitz's co-authors include Dennis D. Cunningham, Mordechai Sokolovsky, Moshe Rehavi, Abraham Fisher, Jeantine E. Lunshof, Abraham Weizman, Noam Shomron, Ralph Bradshaw, Rachel Haring and K. P. Cavanaugh and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

David Gurwitz

188 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics

2020 571 citations David Gurwitz Drug Development Research profile →

Peers

Countries citing papers authored by David Gurwitz

Since Specialization

Citations

This map shows the geographic impact of David Gurwitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Gurwitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Gurwitz more than expected).

Fields of papers citing papers by David Gurwitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Gurwitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Gurwitz. The network helps show where David Gurwitz may publish in the future.

Co-authorship network of co-authors of David Gurwitz

This figure shows the co-authorship network connecting the top 25 collaborators of David Gurwitz. A scholar is included among the top collaborators of David Gurwitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Gurwitz. David Gurwitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Nitrosative Stress in Autism: Supportive Evidence and Implications for Mitochondrial Dysfunction 2024 ·Advanced Science ·Richard E. Frye, (unknown), (unknown), David Gurwitz	6
2	RNA sequencing comparing centenarian and middle‐aged women lymphoblastoid cell lines identifies age‐related dysregulated expression of genes encoding selenoproteins, heat shock proteins, CD99, and BID 2024 ·Drug Development Research ·(unknown), (unknown), (unknown), (unknown), Monika Puzianowska‐Kuźnicka, Noam Shomron, David Gurwitz	0
3	Enriching iPSC research diversity: Harnessing human biobank collections for improved ethnic representation 2024 ·Drug Development Research ·David Gurwitz, Rachel Steeg	1
4	Immunoglobulin genes expressed in lymphoblastoid cell lines discern and predict lithium response in bipolar disorder patients 2023 ·Molecular Psychiatry ·(unknown), Ashwani Choudhary, (unknown), (unknown), Elena Milanesi, John R. Kelsoe, David Gurwitz, Martin Alda, Fred H. Gage, Shani Stern	7
5	Impaired myelin ultrastructure is reversed by citalopram treatment in a mouse model for major depressive disorder 2023 ·Journal of Psychiatric Research ·(unknown), Hope Pan, (unknown), Nir Pillar, (unknown), Boaz Barak, Ana M.D. Carneiro, David Gurwitz, Noam Shomron	3
6	Blood transcriptional response to treatment-resistant depression during electroconvulsive therapy 2021 ·Journal of Psychiatric Research ·(unknown), Libi Hertzberg, Guy Shapira, Aviv Segev, Israel Krieger, Uri Nitzan, Yuval Bloch, Nir Pillar, (unknown), Abraham Weizman, David Gurwitz, Noam Shomron	12
7	Peripheral Blood Mononuclear Cell Oxytocin and Vasopressin Receptor Expression Positively Correlates with Social and Behavioral Function in Children with Autism 2019 ·Scientific Reports ·(unknown), Sirish C. Bennuri, (unknown), Richard E. Frye, Shannon Rose, David Gurwitz	19
8	Identification of thioredoxin-interacting protein (TXNIP) as a downstream target for IGF1 action 2018 ·Proceedings of the National Academy of Sciences ·Karthik Nagaraj, (unknown), Rive Sarfstein, David Gurwitz, Metsada Pasmanik‐Chor, Zvi Laron, Shoshana Yakar, Haim Werner	49
9	A gene co-expression module implicating the mitochondrial electron transport chain is associated with long-term response to lithium treatment in bipolar affective disorder 2018 ·Translational Psychiatry ·David Stacey, Klaus Oliver Schubert, Scott R. Clark, Azmeraw T. Amare, Elena Milanesi, Carlo Maj, Susan G. Leckband, Tatyana Shekhtman, John R. Kelsoe, David Gurwitz, Bernhard T. Baune	21
10	Decreased sensitivity to paroxetine-induced inhibition of peripheral blood mononuclear cell growth in depressed and antidepressant treatment-resistant patients 2016 ·Translational Psychiatry ·(unknown), (unknown), (unknown), Marcin Siwek, Dominika Dudek, (unknown), (unknown), Noam Shomron, David Gurwitz, Andrzej Pilc	12
11	Neuronal cell adhesion genes and antidepressant response in three independent samples 2015 ·The Pharmacogenomics Journal ·Chiara Fabbri, Concetta Crisafulli, David Gurwitz, Julia Stingl, Raffaella Calati, Diego Albani, Gianluigi Forloni, Marco Calabrò, (unknown), Siegfried Kasper, Joseph Zohar, Alzbeta Juven‐Wetzler, Daniel Souery, Stephen B. Montgomery, Julien Mendlewicz, Giovanni de Girolamo, Alessandro Serretti	26
12	Grant Application Review: The Case of Transparency 2014 ·PLoS Biology ·David Gurwitz, Elena Milanesi, Thomas Koenig	17
13	Genome-Wide miRNA Expression Profiling of Human Lymphoblastoid Cell Lines Identifies Tentative SSRI Antidepressant Response Biomarkers 2012 ·Pharmacogenomics ·(unknown), (unknown), Metsada Pasmanik‐Chor, Varda Oron‐Karni, Noam Shomron, Moshe Rehavi, Julia Stingl, David Gurwitz	59
14	The EU-ADR corpus: Annotated drugs, diseases, targets, and their relationships 2012 ·Journal of Biomedical Informatics ·Erik M. van Mulligen, Annie Fourrier‐Réglat, David Gurwitz, Mariam Molokhia, Ainhoa Nieto, Gianluca Trifirò, Jan A. Kors, Laura I. Furlong	92
15	Thrombin receptor PAR-1 on myelin at the node of Ranvier: a new anatomy and physiology of conduction block 2008 ·Brain ·Eran Shavit, (unknown), Amos D. Korczyn, (unknown), (unknown), Vivian E. Drory, David Gurwitz, Ido Horresh, Rachel Bar‐Shavit, Elior Peles, Joab Chapman	34
16	Invited Abstracts 2006 ·Journal of Pharmacy and Pharmacology ·Abdul W. Basit, David Gurwitz, Munir Pirmohamed, Jeantine E. Lunshof, Michael J. Zaworotko, Ivan Marziano, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	4
17	Ethnic differences in CYP2C92 (Arg144Cys) and CYP2C93 (Ile359Leu) genotypes in Japanese and Israeli populations 2005 ·Life Sciences ·Kenji Nakai, Wataru Habano, (unknown), (unknown), Noriko Fukushima, Akira Suwabe, Shogo Moriya, (unknown), David Gurwitz	35
18	Giant axonal neuropathy (GAN): Case report and two novel mutations in the gigaxonin gene 2002 ·Neurology ·Michael Graham Espey, Anthony S. Basile, Robert K. Heaton, Ronald Ellis, San Diego, David Gurwitz, Joab Chapman, (unknown), Eelco F. M. Wijdicks, Edward D. Gomperts, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2
19	Novel 5-HT1A-receptor agonists: F11440, MKC242 and BAYx3702 1999 ·Drug Discovery Today ·David Gurwitz	11
20	Selective neurotoxicity induced by lasalocid in dissociated cerebral cultures 1993 ·Toxicology in Vitro ·(unknown), Asher Shainberg, Rachel Haring, David Gurwitz, A. Shahar	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact